Shandong Boan Biotechnology Co Ltd (6955)

Currency in HKD
16.79
-0.29(-1.70%)
Delayed Data·
6955 Scorecard
Full Analysis
Net income is expected to grow this year
6955 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.4016.88
52 wk Range
7.5125.00
Key Statistics
Bid/Ask
16.78 / 16.79
Prev. Close
17.08
Open
16.88
Day's Range
16.4-16.88
52 wk Range
7.51-25
Volume
2.79M
Average Volume (3m)
23.29M
1-Year Change
85.25%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6955 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.41
Downside
-37.97%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Shandong Boan Biotechnology Co Ltd Company Profile

Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of postmenopausal women with osteoporosis; and Boluojia (BA1102), a fully human IgG2 anti-RANKL monoclonal antibody to treat bone metastases from solid tumors, and giant cell tumor of bone. It also develops BA5101, a long-acting glucagon-like peptide-1 receptor agonist intended for glycemic control in adults with type 2 diabetes; BA9101, a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection; BA1104, a monoclonal antibody in Phase 3 clinical trial that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 receptor; BA2101, a long-acting human monoclonal antibody of the IgG4 subtype in Phase 1b/2 trial that targets interleukin-4 receptor subunit a; BA1106, a non-IL-2 blocking anti-CD25 antibody in Phase 1b/2 trial; BA1301, an ADC candidate in Phase 1b/2 trial that targets Claudin 18.2; BA1202, a bi-specific antibody drug in Phase 1a trial that targets CEA/CD3; and BA1302, a CD228-directed ADC in Phase 1a trial. It has an agreement with the Zencore Biologics Co., Ltd. to use its stable cell line development platform non-exclusively, BA-HIEXcell for the development of antibodies and therapeutic proteins. The company was founded in 2013 and is headquartered in Yantai, China. Shandong Boan Biotechnology Co., Ltd. is a subsidiary of Shandong Luye Pharmaceutical Co., Ltd.

Employees
760
Market
Hong Kong

Compare 6955 to Peers and Sector

Metrics to compare
6955
Peers
Sector
Relationship
P/E Ratio
123.4x−28.3x−0.5x
PEG Ratio
0.730.260.00
Price/Book
5.5x7.1x2.6x
Price / LTM Sales
12.4x23.6x3.3x
Upside (Analyst Target)
−39.0%0.2%43.4%
Fair Value Upside
Unlock−13.3%7.1%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 10.41
(-37.97% Downside)

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
0.02 / --
Revenue / Forecast
363.37M / --
EPS Revisions
Last 90 days

6955 Income Statement

FAQ

What Stock Exchange Does Shandong Boan Biotechnology Trade On?

Shandong Boan Biotechnology is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Shandong Boan Biotechnology?

The stock symbol for Shandong Boan Biotechnology is "6955."

What Is the Shandong Boan Biotechnology Market Cap?

As of today, Shandong Boan Biotechnology market cap is 10.63B.

What Is Shandong Boan Biotechnology's Earnings Per Share (TTM)?

The Shandong Boan Biotechnology EPS (TTM) is 0.14.

From a Technical Analysis Perspective, Is 6955 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Shandong Boan Biotechnology Stock Split?

Shandong Boan Biotechnology has split 0 times.

How Many Employees Does Shandong Boan Biotechnology Have?

Shandong Boan Biotechnology has 760 employees.

What is the current trading status of Shandong Boan Biotechnology (6955)?

As of 08 Aug 2025, Shandong Boan Biotechnology (6955) is trading at a price of 16.79, with a previous close of 17.08. The stock has fluctuated within a day range of 16.40 to 16.88, while its 52-week range spans from 7.51 to 25.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.